CSIMarket
 
Nanobiotix S a   (NBTX)
Other Ticker:  
 
 
Price: $6.9500 $0.69 11.022%
Day's High: $7 Week Perf: 2.96 %
Day's Low: $ 6.05 30 Day Perf: -2.93 %
Volume (M): 58 52 Wk High: $ 11.00
Volume (M$): $ 402 52 Wk Avg: $6.59
Open: $6.11 52 Wk Low: $1.75



 Market Capitalization (Millions $) 242
 Shares Outstanding (Millions) 35
 Employees -
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -64
 Cash Flow (TTM) (Millions $) 94
 Capital Exp. (TTM) (Millions $) 0

Nanobiotix S A
Nanobiotix S is a French clinical-stage nanomedicine company that is pioneering a new approach to cancer therapy. The company's proprietary technology platform, NanoXray, uses nanoparticles to increase the efficacy of radiotherapy and other cancer treatment modalities.

NanoXray technology involves the use of nanoparticles made of hafnium oxide, a material that is able to absorb X-rays and release the energy in a controlled manner. When these nanoparticles are injected into a tumor, they accumulate within cancer cells and, when exposed to X-ray radiation, they generate a localized burst of radiation that increases the effectiveness of the treatment.

Nanobiotix S is currently developing a suite of products based on the NanoXray technology platform, including NBTXR3, which is a radioenhancer designed to be used in conjunction with radiotherapy for the treatment of solid tumors. The company is also exploring the potential of NanoXray in combination with other cancer therapies, such as immunotherapy.

In addition to its NanoXray technology, Nanobiotix S is also working on the development of a pipeline of other nanomedicines focused on oncology and other diseases. The company is committed to bringing its innovative technology to patients and improving outcomes for those fighting cancer.


   Company Address: 60 rue de Wattignies Paris 75012
   Company Phone Number: (0)1 40 26 04 70   Stock Exchange / Ticker: NASDAQ NBTX
   NBTX is expected to report next financial results on April 23, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

Nanobiotix Hits $20M Milestone Payment in Global Phase 3 Head and Neck Cancer Study

Published Mon, Jan 29 2024 9:15 PM UTC



Nanobiotix, a leading biotechnology company specializing in physics-based approaches to revolutionize cancer treatment, has recently achieved a significant milestone in their ongoing global Phase 3 study. The study aims to evaluate the potential of NBTXR3, a first-in-class radioenhancer, in elderly patients suffering from head and neck cancer. As a result of succes...

Shares

Fairfax Expands Holdings in Mining Sector with Acquisition of 500,000 Orla Mining Shares.

Published Thu, Jan 11 2024 9:32 PM UTC

Voting Rights and Share Capital of the Company: Fairfax Announces Acquisition of Additional Orla Shares
Toronto-based Fairfax Financial Holdings Limited (Fairfax) has recently made a significant move in the mining industry, announcing the acquisition of 500,000 common shares of Orla Mining Ltd. (Orla) through its insurance company subsidiaries. The purchase was made at a...

Shares

Fairfax Financial Holdings Acquires 500,000 Common Shares of Orla Mining Ltd for $2.1 million, Impacting Shareholders and Setting Context for Previous News

Published Wed, Jan 10 2024 12:50 PM UTC



Toronto-based Fairfax Financial Holdings Limited (Fairfax) announced its recent acquisition of 500,000 common shares of Orla Mining Ltd. through its insurance company subsidiaries. The purchase of the common shares, priced at $4.20 per share, amounts to an aggregate purchase price of approximately $2,100,000. The transaction was facilitated through the Toronto Stoc...

Contract

Nanobiotix's NBTXR3 Breakthrough Cancer Treatment Finds New Horizons in Asia with Janssen Partnership.

Published Tue, Dec 26 2023 7:00 AM UTC

Nanobiotix's Groundbreaking Cancer Treatment, NBTXR3, Gains Momentum in Asian MarketsParis and Cambridge, Mass. - In a significant development, Nanobiotix, a renowned biotechnology company focused on advancing innovative physics-based approaches for cancer treatment, has announced that its strategic partner, LianBio, has assigned its development and commercialization rights ...

Shares

Nanobiotix S.A.: Cultivating Trust and Growth Through Voting Rights and Shares Capital

Published Wed, Dec 13 2023 9:15 PM UTC



In a recent press release, Nanobiotix S.A. disclosed crucial information pertaining to the company's voting rights and shares capital. As per the regulations set forth by the French Commercial Code and the General Regulation of the French Financial Markets Authority, this article aims to highlight the implications of these facts and assess their impact on the value...






 

Nanobiotix S A's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com